Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)
Status:
Completed
Trial end date:
2015-08-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine maximum tolerated dose (MTD), efficacy, safety and
tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor effect of E7080 when is
administered continually once daily in participants with advanced hepatocellular carcinoma.